Subscribe To
ITCI / Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2022 Results - Earnings Call Transcript
ITCI News
By Zacks Investment Research
November 3, 2023
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth. more_horizontal
By Seeking Alpha
August 12, 2023
Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline
Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed more_horizontal
By Zacks Investment Research
August 4, 2023
Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised
Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. more_horizontal
By Seeking Alpha
May 25, 2023
Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)
Intra-Cellular's drug Caplyta (lumateperone) is advancing through trials for major depressive disorder (MDD), expanding its approved uses beyond schiz more_horizontal
By Zacks Investment Research
March 31, 2023
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? more_horizontal
By Zacks Investment Research
March 29, 2023
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. more_horizontal
By Zacks Investment Research
March 29, 2023
Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate re more_horizontal
By The Motley Fool
March 28, 2023
Why Intra-Cellular Therapies Climbed Tuesday
Caplyta, the company's lead drug, was responsible for most of the company's revenue in 2022. The potential addition of major depressive disorder to th more_horizontal